Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is set to post its quarterly earnings results before the market opens on Monday, October 30th. Analysts expect Lexicon Pharmaceuticals to post earnings of ($0.36) per share for the quarter.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12. The company had revenue of $12.00 million for the quarter, compared to the consensus estimate of $18.34 million. Lexicon Pharmaceuticals had a negative return on equity of 94.87% and a negative net margin of 170.63%. Lexicon Pharmaceuticals’s revenue for the quarter was down 40.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.37) earnings per share. On average, analysts expect Lexicon Pharmaceuticals to post $-1.47 EPS for the current fiscal year and $-0.96 EPS for the next fiscal year.

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) traded down 0.63% during trading on Monday, reaching $11.09. The company’s stock had a trading volume of 15,573 shares. The firm’s market capitalization is $1.17 billion. Lexicon Pharmaceuticals, Inc. has a 52 week low of $10.96 and a 52 week high of $18.00. The company has a 50 day moving average price of $12.54 and a 200 day moving average price of $14.75.

LXRX has been the topic of several research analyst reports. Needham & Company LLC reissued a “buy” rating and set a $21.00 price target on shares of Lexicon Pharmaceuticals in a research note on Sunday, September 17th. BidaskClub lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, June 29th. Cowen and Company reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, August 1st. Zacks Investment Research raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. Finally, Wedbush reissued an “ourperform” rating and set a $39.00 price target on shares of Lexicon Pharmaceuticals in a research note on Monday, August 7th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $28.75.

In related news, insider Lonnel Coats bought 30,000 shares of Lexicon Pharmaceuticals stock in a transaction that occurred on Friday, September 15th. The shares were purchased at an average price of $12.54 per share, with a total value of $376,200.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 5.77% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/23/lexicon-pharmaceuticals-inc-lxrx-set-to-announce-earnings-on-monday.html.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Earnings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.